

SPARC/Sec/SE/2024-25/47

November 04, 2024

National Stock Exchange of India Ltd.,

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. **BSE Limited,**Market Operations Dept.
P. J. Towers,
Dalal Street,

Scrip Code: 532872

Mumbai - 400 001.

Scrip Symbol: SPARC

Dear Sir/ Madam,

Sub: Clarification - Financial Results for the quarter and half year ended September 30, 2024

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), the Board of Directors of the Company at its meeting held on November 04, 2024, had considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2024.

In this regard, we would like to inform you that the Company had filed the Financial Results in Compliance with Regulation 30 and Regulation 33 of the Listing Regulation vide Ref Id: 8152906 within the stipulated time period but inadvertently missed to include Cash Flow in PDF file. Hence, we hereby uploading once again the Unaudited Standalone and Consolidated Financial Results of the Company, for the quarter and half year ended September 30, 2024 with the Complete PDF file.

Kindly take the same in your record.

For Sun Pharma Advanced Research Company Limited.

Kajal Damania Company Secretary and Compliance Officer

Encl: As above



Ground Floor Panchshil Tech Park, Yerwada (Near Don Bosco School) Pune - 411 006, India

Tel: +91 20 6603 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Sun Pharma Advanced Research Company Limited

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results of Sun Pharma Advanced Research Company Limited (the "Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group"), for the quarter ended September 30, 2024 and year to date from April 01, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Holding Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the entity	Relationship
SPARCLIFE, Inc.	Subsidiary

(This space is intentionally left blank)



SRBC&COLLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

C

HARTERS

per Amit Singh

Partner

Membership No.: 408869

UDIN: 24408869 BKBTUX6854

Place: Mumbai

Date: November 04, 2024

Regd. Office. Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway,

Manjusar, Vadodara - 391 775, Tel. : +91-2667 666800 CIN: L73100GJ2006PLC047837, Website: www.sparc.tife

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year Ended September 30, 2024

Fin Lakhe

	Quarter ended			Half Year ended		Year ended	
Particulars	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Revenue from operations	1,286	1,681	2,118	2,967	4.513	7,555	
Other income	4	156	849	160	1,868	2,947	
Total income	1,290	1,837	2,967	3,127	6,381	10,502	
Expenses						,	
Cost of materials consumed	831	453	647	1,284	1,164	2,813	
Employee benefits expense	3,848	5,426	3,071	9,274	6,183	14,184	
Clinical trial expenses / products development expense	2,553	1,854	1.821	4,407	5,519	10,135	
Professional charges	3,075	2,200	4,188	5,275	8,323	15,246	
Finance costs	114	56	26	170	52	169	
Depreciation and amortisation expense	316	314	318	630	628	1,251	
Other expenses	1,270	1,084	1,538	2.354	2,689	5,387	
Total expenses	12,007	11,387	11,609	23,394	24,558	49,185	
Profit / (loss) before tax	(10,717)		(8,642)	(20,267)	(18,177)	(38,683)	
Tax expense	16	40	, , ,	56	(,,	38	
Profit / (loss) for the period	(10,733)	(9,590)	(8,642)	(20,323)	(18,177)	(38,721)	
Other comprehensive income (OCI)	, , ,		,,,,,,	(,,	(,,	[,	
a. Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)	4	5	34	9	68	19	
 b. Items that may be reclassified to profit or loss (exchange differences in translating the financial statements of subsidiary) 	1	(0)	-	1	_	1	
Total comprehensive profit / (loss) for the period	(10,728)	(9,585)	(8,608)	(20,313)	(18,109)	(38,701)	
Attributable to:	1	()	(/ / /	(=-,,	(,,	(,,	
- Owners of the Company	(10,728)	(9,585)	(8,608)	(20,313)	(18,109)	(38,701)	
- Non-contolling interests			``.	`			
Paid-up equity share capital (Face value ₹ 1 each)	3,245	3,245	3,245	3,245	3,245	3,245	
Other equity	-,	0,2.0	0,2.0	5,2,10	0,240	9,330	
Basic and diluted earning / (loss) per equity share of ₹ 1 each	(3.31)	(2.96)	(2.66)	(6.26)	(5.60)	(11.93)	
	Not annualised	Not annualised	Not annualised	Not annualised	Not annualised	Annualised	
All "0" represents amounts less than ₹ 1 Lakh.	, tot annualised		, tot connection	not annuansed	1401 allinaniscu	Ailliuailseu	
See accompanying notes to the unaudited consolidated financial results							

Notes:


- These unaudited consolidated financial results relate to Sun Pharma Advanced Research Company Limited (the 'Company') and its Wholly Owned Subsidiary (together the 'Group') and are prepared by applying Ind AS 110 - "Consolidated Financial Statements".
- The above unaudited consolidated financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 4, 2024.
- The above unaudited consolidated financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- The Group has incurred cash losses in past quarters and in the current quarter. The Group has unutilized credit limits and support letter from its promoter group entity basis which its status as "Going Concern" continues.
- The Group has only one reportable business segment namely 'Pharmaceutical Research and Development'.
- Previous period figures have been regrouped / reclassified, wherever considered necessary.

Dilip S. Shanghvi

Chairman

Mumbai, November 4, 2024





Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway, Manjusar, Vadodara – 391 775. Tel.: +91-2667 666800 CIN: L73100GJ2006PLC047837. Website: www.sparc.life

Unaudited Consolidated Balance Sheet as at September 30, 2024

Particulars	As at 30.09.2024 Unaudited	₹ in Lakh As at 31.03.2024 Audited
ASSETS		
(A) Non-current assets		
(a) Property, plant and equipment	10,432	10,735
(b) Capital work-in-progress	33	126
(c) Other intangible assets	11	120
(d) Intangible assets under development	4,253	4,253
(e) Financial assets	4,233	4,200
(i) Other financial assets	2,561	2 5 40
(f) Deferred tax assets (net)	71	2,549
(g) Income tax assets (net)	5,619	126
(h) Other non-current assets	3,619	6,678
Total non-current assets (A)	23,026	24,566
(B) Current assets		
(a) Financial assets		
(i) Investments	40	180
(ii) Trade receivables	1,342	1,553
(iii) Cash and cash equivalents	567	533
(iv) Bank balances other than (iii) above	367	15,000
(v) Loans	19	
(vi) Other financiat assets	373	4 270
(b) Other current assets		4,279
Total current assets (B)	6,714 9,055	5,371 26,938
TOTAL ASSETS	32,081	51,504
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	3,245	2 245
(b) Other equity		3,245
Total equity	(10,983) (7,738)	9,330 12,575
Liabilities		
(A) Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	900	4 000
(ii) Other financial liabilities	883	1,066
(b) Provisions	84	403
(c) Other non-current liabilities	605	605
Total non-current liabilities (A)	10,349 11,921	10,350 12,424
B) Current liabilities		
(a) Financial liabilities		
(i) Borrowings	0.075	4 700
(ia) Lease liabilities	8,875	4,700
(ii) Trade payables	363	349
- Total outstanding dues of micro enterprises and small enterprises		
Total outstanding dues of inclo exceptions and single prises	88	106
 Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities 	13,945	14,123
	3,377	4,332
	456	1,506
(c) Provisions (d) Current tax liabilities (net)	794	1,224
otal current liabilities (B)	27,898	165 26,505
Total Debugger	39,819	38,929
otal liabilities		





Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D.C. Estate, Savli - Vadodara Highway, Manjusar Vadodara - 391 775. Tel.: +91-2667 666800

CIN L73100GJ2006PLC047837 Website www.sparc.life

Unaudited Consolidated Statement of Cash Flow for Half Year Ended September 30, 2024

		₹ in Lakhs
Particulars	Half Year ended 30,09,2024	Haif Year ended 30.09.2023
	Unaudited	Unaudited
A. Cash flow from operating activities		
Loss before tax	(20,267)	(18,177)
Adjustments to reconcile loss before tax to net cash flows:		
Depreciation and amortisation expense	630	628
Gain on disposal of property, plant and equipment (net)	(3)	(3
Finance costs	170	52
Interest income	(50)	(1,654)
Net gain on sale of financial assets measured at fair value through profit or loss	(105)	(172
Net gain arising on financial assets measured at fair value through profit or loss	(0)	(24
Net unrealised foreign exchange loss / (gain)	(23)	428
Provision for doubtful debt	(23)	205
Operating loss before working capital changes	(19,648)	(18,717)
Working capital adjustments :	(10,040)	(10,717)
(Increase) / decrease in trade receivables	040	
(Increase) / decrease in other assets	213	(98)
Increase / (decrease) in trade payables	1,210	(1,909)
Increase / (decrease) in other liabilities	(211)	1,916
Increase / (decrease) in provisions	(2,263)	(204)
Cash used in operations	(423)	(48)
Direct tax (paid) / refund received (including interest on refunds) (net)	(21,122) 894	(19,060)
Net cash used in operating activities (A)	(20,228)	(243)
B. Cash flow from investing activities	(12,000)	(10,000)
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development)	(357)	(504)
Proceeds from disposal of property, plant and equipment	42	23
Redemption of investment (net)	245	14,144
Fixed deposits with bank placed		(2,500)
Fixed deposits with bank matured	15,000	7,262
Interest received	1,455	1,120
Net cash generated / (used in) investing activities (B)	16,385	19,545
C. Cash flow from financing activities		
Proceeds from borrowings	9.987	190
Repayment of borrowings	(5,812)	(195)
Repayment of principal portion of lease liabilities	(171)	(112)
Finance costs (including interest on lease liabilities)	(128)	(52)
Net cash generated in financing activities (C)	3,876	(169)
Net Increase / (decrease) in cash and cash equivalents (A+B+C)	33	73
Cash and cash equivalents at the beginning of the year	533	58
Effect of exchange differences on restatement of foreign currency cash and cash equivalents	1	-
Cash and cash equivalents at the end of the period	567	131
Il "0" represents amounts less than ₹ 1 Lakh.		







Ground Floor Panchshil Tech Park, Yerwada (Near Don Bosco School) Pune - 411 006, India Tel: +91 20 6603 6000

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to The Board of Directors Sun Pharma Advanced Research Company Limited

- We have reviewed the accompanying statement of unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the "Company") for the quarter ended September 30, 2024 and year to date from April 01, 2024 to September 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SRBC&COLLP Chartered Accountants

ICAI Firm registration number: 324982E/E300003

8 0

COLLA

CHARTERED

per Amit Singh

Partner

Membership No.: 408869

UDIN: 2440 8869 BKBT UY1495

Place: Mumbai

Date: November 04, 2024

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway, Manjusar, Vadodara – 391 775. Tel: +91-2667 666800 CIN: L73100GJ2006PLC047837. Website: www.sparc.life

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year Ended September 30, 2024

₹ in Lakhs

		Quarter ended			Half Year ended	
Particulars	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	1,286	1,681	2,118	2,967	4,513	7,555
Other income	4	156	849	160	1,868	2,947
Total income	1,290	1,837	2,967	3,127	6,381	10,502
Expenses						
Cost of materials consumed	831	453	647	1,284	1,164	2,813
Employee benefits expense	2,878	2,894	3,071	5,772	6,183	11,853
Ctinical trial expenses / products development expense	2,553	1,854	1,821	4,407	5,519	10,135
Professional charges	4,141	4,910	4,188	9,051	8,323	17,889
Finance costs	111	52	26	163	52	166
Depreciation and amortisation expense	277	276	318	553	628	1,213
Other expenses	1,268	1,082	1,538	2,350	2,689	5,244
Total expenses	12,059	11,521	11,609	23,580	24,558	49,313
Profit / (loss) before tax	(10,769)	(9,684)	(8,642)	(20,453)	(18,177)	(38,811
Tax expense		,		-		
Profit / (loss) for the period	(10,769)	(9,684)	(8,642)	(20,453)	(18,177)	(38,811
Other comprehensive income (OCI)					` ' '	
Items that will not be reclassified to profit or loss (net actuarial gain / (loss) on employee defined benefit plan)	4	5	34	9	68	19
Total comprehensive profit / (loss) for the period	(10,765)	(9,679)	(8,608)	(20,444)	(18,109)	(38,792
Paid-up equity share capital (Face value ₹ 1 each)	3,245	3,245	3,245	3,245	3,245	3,245
Other equity						9.240
Basic and diluted earning / (loss) per equity share of ₹ 1 each	(3.32)	(2.98)	(2.66)	(6.30)	(5.60)	(11.96
	Not annualised		Not annualised	Not annualised	Not annualised	Annualised
See accompanying notes to the unaudited standalone financial results						

Notes:

- 1 The above unaudited standalone financial results of Sun Pharma Advanced Research Company Limited (the 'Company') have been prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and have been taken on record by the Board of Directors at its meeting held on November 4, 2024 after being reviewed by the Audit Committee.
- 2 The Company has incurred cash losses in past quarters and in the current quarter. The Company has unutilized credit limits and support letter from its promoter group entity basis which its status as "Going Concern" continues.
- 3 The Company has only one reportable business segment namely 'Pharmaceutical Research and Development'.
- 4 Previous period figures have been regrouped / reclassified, wherever considered necessary.

For and on behalf of the Board

Dilip S. Shanghvi

Chairman

Mumbai, November 4, 2024



INITIAL FOR IDENTIFICATION
BY
SMEC 8. CO LLP

Regd. Office: Plot No. 5 & 6/1, Savli, G. I. D. C. Estate, Savli - Vadodara Highway, Manjusar, Vadodara - 391 775, Tel.: +91-2667 666800 CIN: L73100GJ2006PLC047837. Website: www.sparc.life

Unaudited Standalone Balance Sheet as at September 30, 2024

ASSETS (A) Non-current assets (A) Property, pleat and equipment (b) Capital work-exprogress (c) Other intangible assets (d) Intangible assets (d) Intangible assets (e) Financial assets (f) Other financial assets (f) Investment in the native of equity in subsidiary (g) Other financial assets (g) Investment in the native of equity in subsidiary (g) Income tax assets (n) (h) Other financial assets (g) Investment assets (g) Other current assets (g) Investment assets	Particulars		As at 30.09.2024 Unaudited	₹ in Lakh As at 31.03.2024 Audited	
(a) Property, plant and equipment (b) Caplat burknin-propers (c) Caplat burknin-propers (d) Caplat burknin-propers (d) Other intangible assets under development (e) Financial assets (f) Interpretare in the nature of equity in subsidiany (g) Other financial assets (g) Income tax assets (net) (g) Income tax assets (g) Financial ass	ASSETS			NIET II	
(b) Capital work-in-progress	(A) Non-current a	ssets			
(b) Capital work-in-progress (c) Other infanagible assets under development (d) Intangible assets under development (d) Intangible assets under development (d) Intangible assets (d) (in westment in the nature of equity in subsidiary (d) Intended is assets (ret) (d) Other financial assets (d) (in westment assets (ret) (d) Income tax assets (d) (d) Income tax assets (d) (d) Income tax assets (d) (e) Income tax assets (d) (f) Income tax assets (d) (• •		10.019	10,246	
(c) Other inlangible assets (1) (1) (Inlangible assets) (2) (2) Financial assets (3) (2) Financial assets (3) (3) Prinarcial assets (4) (4) (3) Other financial assets (4) (4) Other financial assets (4) (5) Other financial assets (4) (5) Other ron-current assets (5) (6) Other ron-current assets (6) (7) Other ron-current assets (7) Other ron-current assets (7) Other ron-current assets (8) (8) Other current assets (8) (9) Other ron-current assets (8) (9) Other ron-current assets (9) Other ron-current assets (9) Other ron-current assets (9) Other ron-current assets (9) (9) Other ron-current assets (9) Other current assets (9) (1) Other ron-current assets (9) (1) Other ron-current assets (9) (1) Other ron-current assets (1) Other current				126	
(d) intangible asselts under development 4,283 (F) Financial asselts 2,561 (i) Owterfinancial insectis 2,561 (j) Deferred tax asselts (ret) 5,604 (j) Income tax asselts (ret) 5,604 (j) Income tax asselts (ret) 4,6 (j) Income tax asselts 22,569 (j) Current asselts 22,569 (j) Income tax asselts 22,569 (j) Income tax asselts 1,40 (j) Income tax asselts 1,342 (ji) Income tax asselts 1,342 (jii) Trade receivables 1,342 (jii) Trade receivables 1,342 (jii) Trade receivables 1,342 (jii) Charis 1,9 (jii) Charis 1,9 (jii) Charis 1,9 (jii) Charis 3,5 (jii) Charis 3,5 (jii) Charis 3,763 (jii) Charis 3,1,322 COTAL ASSETS 31,332 COUTH ADDILITIES 5,00 Equity 3,245 (jii) Charis 1,1,20 <td></td> <td></td> <td></td> <td>19</td>				19	
(e) Financial assets (f) (hymestment in the nature of equity in subsidiary (f) (p) Other financial assets (f) (p) Other financial assets (f) (p) (p) Other financial assets (p) (p) Other financial assets (p) (p) Other financial assets (p) (p) (p) Other financial assets (p) (p) (p) Other financial assets (p) (p) Other financial liabilities (p) Other finan				4,253	
(i) Investment in the nature of equity in subsidiary (ii) Ober financial assets (iii) Ober financial assets (iii) Income tax assets (net) (iii) Income tax assets (net) (iii) Income tax assets (net) (iii) Income tax assets (iii) Investments (iii) Cash and cash equivalents (iii) Cash and cash equivalents (iv) San Ab elainces other than (iii) above (v) Loans (vi) Other nancial assets (iii) Other current sasets (iii) Other nancial assets (iii) Other nancial liabilities (iii) Other equity (iii) Other equity (iii) Other equity (iii) Other nancial liabilities (iii) Other financial liabilities (iii) Other nancial liabilities (iiii) Other nancia					
(ii) Other financial assets (net)		ment in the nature of equity in subsidiary	42	42	
(f) Deferred tax assets (net) (g) Corner tax assets (net) (h) Other non-current assets Total non-current assets (g) Financial assets (g) Other current assets (g) Financial assets (g) Financial assets (g) Financial assets (g) Financial liabilities (h) Financial lia				2,549	
(g) Income tax assets (ref) (h) Other non-current assets (A) 46 Total non-current assets (A) 22,569 (B) Current assets (A) 22,569 (g) Financial assets (A) 22,569 (g) Financial assets (h) 40 (ii) Trade receivables 40 (iii) Trade receivables 40 (iii) Trade receivables 40 (iii) Cash and cash equivalents 299 (iv) Dank balances other than (iii) above 70 (v) Loans 199 (vi) Other financial assets 50 (b) Other current assets (B) 355 (c) Other current assets (B) 355 (d) Other current assets (B) 31,332 EQUITY AND LIABILITIES (quity (a) Equity share capital 3,245 (b) Other current assets (B) (7,989) Liabilities (a) Financial inabilities (b) Chase liabilities (c) Lease liabilities (c) Cher non-current liabilities (c) Cher non-current liabilities (d) 11,851 B) Current liabilities (a) 12,349 (c) Other non-current liabilities (a) 12,349 (c) Other con-current liabilities (b) 12,349 (c) Other con-current liabilities (a) 11,851 (b) Other current liabilities (b) 12,349 (c) Other con-current liabilities (c) 12,459 (c) Other con-current liabilities (c) 12,569 (c) Other con-current liabilities (c) 14,797 (iii) Other current liabilities (c) 2,668 (b) Other current liabilities (c) 2,668 (c) Other cur				2,0	
(i) Other non-current assets (A) 22,569 (B) Current assets (a)			5.604	6,678	
Total non-current assets A				80	
(B) Current assets (a) Financial assets (b) Investments (c) Investments (d) Financial assets (e) Investments (ii) Trade receivables (iv) Bank balances other than (iii) above (v) Loans (v) Other financial assets (b) Other current assets (c) Other current assets (d) Other current assets (e) Other current assets (folial current assets (folial) (folial current assets (folial) (folial current assets (folial) (• •			23,993	
(a) Financial assets (i) Investments (ii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (v) Other financial assets (b) Other current assets (c) Other current assets (d) Bank balances other than (iii) above (v) Loans (vi) Other financial assets (d) Other current assets (e) Other current assets (f) Other current assets (g) 6,708 (g) Other current assets (g) 7,783 (g) Equity AND LIABILITIES (guity AND LIABILITIES (guity Share capital 3,245 (g) Other equity (g) Equity share capital 3,245 (g) Other equity (g) Equity share capital 4,11,204 (g) Equity share capital 5,7,7,559 (g) Other equity (g) Equity share capital 6,11,204 (g) Equity share capital 6,11,204 (g) Other equity (g) Equity share capital 7,7,559 (g) Other equity (g) Equity share capital 9,11,204 (g) Equity share capital 1,1,204 (g) Other equity (g) Equity share capital 1,1,204 (g) Other equity (g) Equity share capital 1,1,204 (g) Equity share capital 1,1,20					
(i) Investments (ii) Trade receivables (iii) Cash and cash equivalents (iv) Bark balances other than (iii) above (v) Loans (v) Other financial assets (v) Other financial assets (vi) Other current assets (b) Other current assets (c) Other current assets (d) Other current assets (e) Other current assets (f) Other current assets (g) Other equity (g) Equity share capital (h) Other financial liabilities (h) Lease liabilities (h) Equity share capital (h) Other financial liabilities (h) Equity share capital (h) Other financial liabilities (h) Equity share capital (h) Other financial liabilities (h) Equity share capital (h) Equity share capital (h) Equity share capital (h) Other financial liabilities (h) Equity share capital (h) Equity share capital (h) Other financial liabilities (h) Equity share capital (h) Equ					
(ii) Trade receivables			40	180	
(iii) Cash and cash equivalents (iv) Bank balances other than (iii) above (v) Loans (vi) Other financial assets (b) Other current assets (c) Other current assets (d) Other current assets (e) Other capital (for a capi				1,553	
(iv) Bank balances other than (iii) above (v) Loans			1	506	
(v) Char (vi) Char financial assets 35 355 6,706			200	15,000	
(vi) Other financial assets (b) Other current assets (c) Other current assets (d) Other current assets (d) (e) Other current assets (e) (e) Other capital (e) (e) (e) Other capital (e) (e) (e) Other capital (e)			10	13,000	
Cotal current assets				2,067	
Total current assets (B) 8,763 TOTAL ASSETS				5,312	
COTAL ASSETS 31,332 COUNTY AND LIABILITIES COUNTY AND LIABILITI				24,640	
EQUITY AND LIABILITIES Equity (a) Equity share capital 3,245 (b) Other equity (11,204) Total equity (7,959) Liabilities (a) Financial liabilities (i) Lease liabilities (i) Under financial liabilities (ii) Other financial liabilities (b) Provisions 605 (c) Other non-current liabilities 10,349 Total non-current liabilities 10,349 Total non-current liabilities (2) 11,651 (B) Current liabilities (3) 11,651 (B) Current liabilities (4) 11,651 (b) Borrowings 8,875 (ia) Lease liabilities 211 (ii) Trade payables 211 (iii) Trade payables 14,797 (iii) Other financial liabilities 2,568 (b) Other current liabilities 2,568 (b) Other current liabilities 4,645	Total culterit asset	s (D)	8,793	24,040	
Equity (a) Equity share capital 3.245 (b) Other equity (11,204) Total equity Liabilities (A) Non-current liabilities (a) Financial liabilities (ii) Other financial liabilities (iii) Other financial liabilities (c) Other non-current liabilities (d) Deprovings (a) Financial liabilities (ii) Borrowings (iii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other financial liabilities (b) Other current liabilities (b) Other current liabilities (iii) Other financial liabilities (iii) Trade payables - Total outstanding dues of creditors other than micro enterprises and	IOIAL ASSETS		31,332	48,633	
(a) Equity share capital 3,245 (b) Other equity (11,204) Total equity Total equity Total equity Total equity (7,959) Liabilities (a) Financial liabilities (i) Other financial liabilities (c) Other non-current liabilities (d) Financial liabilities (a) Financial liabilities (i) Borrowings (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (iii) Other financial liabilities (iii) Other financial liabilities (b) Other current liabilities (a) Foreign (a) Lease liabilities (iii) Trade payables - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilit		LITIES			
(b) Other equity (11,204) Total equity (7,959) Liabilities (7,959) Liabilities (a) Financial liabilities (i) Lease liabilities 613 (b) Provisions 605 (c) Other non-current liabilities 10,349 Total non-current liabilities 11,851 (B) Current liabilities (i) Borrowings 8,875 (a) I Lease liabilities (ii) Trade payables 211 (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises 88 - Total outstanding dues of creditors other than micro enterprises and small enterprises 14,797 (iii) Other financial liabilities 2,568 (b) Other current liabilities 456 (c) Provisions 456 (d) Other financial liabilities 14,797 (iii) Other financial liabilities 14,797 (iii) Other financial liabilities <th col<="" td=""><td></td><td>are equital</td><td>2017</td><td></td></th>	<td></td> <td>are equital</td> <td>2017</td> <td></td>		are equital	2017	
Total equity				3,245	
Liabilities (A) Non-current liabilities (a) Financial liabilities 613 (i) Lease liabilities 613 (b) Provisions 605 (c) Other non-current liabilities 10,349 Total non-current liabilities (A) (B) Current liabilities 11,651 (a) Financial liabilities 8,875 (ia) Lease liabilities 211 (ii) Trade payables 211 - Total outstanding dues of micro enterprises and small enterprises 88 - Total outstanding dues of creditors other than micro enterprises and small enterprises 14,797 (iii) Other financial liabilities 2,568 (b) Other current liabilities 456 (c) Provisions 645		iity		9,240	
(A) Non-current liabilities (a) Financial liabilities (i) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Other non-current liabilities (d) Other non-current liabilities (d) Other non-current liabilities (e) Other non-current liabilities (f) Eurrent liabilities (g) Financial liabilities (ii) Borrowings (ia) Lease liabilities (iii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (ib) Other current liabilities (c) Provisions (d) Other current liabilities (d) Other current liabilities (e) Provisions	lotal equity		(7,959)	12,485	
(a) Financial liabilities (i) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Other non-current liabilities (d) Other non-current liabilities (e) Other non-current liabilities (f) Eurrent liabilities (g) Financial liabilities (g) Financial liabilities (i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other current liabilities (iii) Other current liabilities (b) Other current liabilities (c) Provisions					
(i) Lease liabilities (ii) Other financial liabilities (b) Provisions (c) Other non-current liabilities (c) Other non-current liabilities (d) Financial liabilities (a) Financial liabilities (i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other financial liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (iii) Other current liabilities (c) Provisions					
(ii) Other financial liabilities (b) Provisions (c) Other non-current liabilities (a) Financial liabilities (a) Financial liabilities (i) Borrowings (i) Borrowings (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions					
(b) Provisions (c) Other non-current liabilities Total non-current liabilities (A) (B) Current liabilities (a) Financial liabilities (i) Borrowings (i) Borrowings (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions				721	
(c) Other non-current liabilities (a) Financial liabilities (a) Financial liabilities (i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions				83	
Total non-current liabilities (A) (a) Financial liabilities (i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions 11,651 11,651 11,651 18,875 8,875 19,11 10,11 11,651	• '			605	
(a) Financial liabilities (i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions	, ,			10,350	
(a) Financial liabilities (i) Borrowings 8,875 (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions 8,875 88 14,797 2,568 456 645	fotal non-current i	abilities (A)	11,651	11,759	
(i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions 8,875 211 88 - Total outstanding dues of creditors other than micro enterprises and small enterprises 14,797 (iii) Other financial liabilities 456 (c) Provisions	B) Current liabilit	es			
(i) Borrowings (ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions 88 - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other current liabilities (5) Other current liabilities (6) Other current liabilities (6) Provisions	(a) Financial	liabilities			
(ia) Lease liabilities (ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises 14,797 (iii) Other financial liabilities (b) Other current liabilities 456 (c) Provisions		ings	8.875	4,700	
(ii) Trade payables - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises - Total outstanding dues of creditors other than micro enterprises - Total outstanding dues of creditors other than micro enterprises - Total outstanding	(ia) Lease	liabilities		202	
- Total outstanding dues of micro enterprises and small enterprises - Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions 88 14,797 2,568 456 645					
- Total outstanding dues of creditors other than micro enterprises and small enterprises (iii) Other financial liabilities (b) Other current liabilities (c) Provisions 14,797 2,568 456 645			88	106	
(iii) Other financial liabilities (b) Other current liabilities (c) Provisions 2,568 456 (d) 456				14,876	
(b) Other current liabilities 456 (c) Provisions 645				2,644	
(c) Provisions 645				1,506	
	• •			355	
Fotal current liabilities (B) 27,640			27,640	24,389	
Fatal Mahillidan	Fotol Bobilles		86.504	00.410	
Fotal liabilities FOTAL EQUITY AND LIABILITIES 39,291 31,332		OLIADU ITIES		36,148 48,633	





Regd. Office: Plot No. 5 & 6/1, Savli, G. 1. D.C. Estate, Savli - Vadodara Highway, Manjusar Vadodara - 391 775. Tel.: +91-2667 666800 CIN: L73100GJ2006PLC047837. Website: www.sparc.life

Unaudited Standalone Statement of Cash Flow for Half Year Ended Ended September 30, 2024

Particulars	Half Year ended 30.09.2024 Unaudited	Half Year ended 30.09.2023 Unaudited
A. Cash flow from operating activities	- Olivariou	- Cildadicoa
Loss before tax	(20,453)	(18,177
Adjustments to reconcile loss before tax to net cash flows:		
Depreciation and amortisation expense	553	628
Gain on disposal of property, plant and equipment (net)	(3)	(3
Finance costs	163	52
Interest income	(50)	(1,654
Net gain on sale of financial assets measured at fair value through profit or loss	(105)	(172
Net gain arising on financial assets measured at fair value through profit or loss	(0)	(24
Net unrealised foreign exchange loss / (gain)	(23)	428
Provision for doubtful debt		205
Operating loss before working capital changes	(19,918)	(18,717
Working capital adjustments:		
(Increase) / decrease in trade receivables	213	(98)
(Increase) / decrease in other assets	(1,042)	(1,909
Increase / (decrease) in trade payables	(116)	1,916
Increase / (decrease) in other liabilities	(1,058)	(204)
Increase / (decrease) in provisions	299	(48)
Cash used in operations	(21,622)	(19,060)
Direct tax (paid) / refund received (including interest on refunds) (net)	1,074	(243)
Net cash used in operating activities (A)	(20,548)	(19,303)
B. Cash flow from investing activities		
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development)	(357)	(504)
Proceeds from disposal of property, plant and equipment		
Redemption of investments (net)	42	23
Fixed deposits with bank placed	245	14,144
Fixed deposits with bank matured		(2,500)
Interest received	15,000	7,262
Net cash generated from investing activities (B)	1,455	1,120
C. Cash flow from financing activities	16,385	19,545
Proceeds from borrowings	9,987	190
Repayment of borrowings		
Repayment of principal portion of lease liabilities	(5,812)	(195)
Finance costs (including interest on lease liabilities)	(120)	(112) (52)
Net cash generated / (used in) financing activities (C)	3,956	(169)
Net Increase / (decrease) in cash and cash equivalents (A+B+C)	(207)	73
Cash and cash equivalents at the beginning of the year	506	7.5 58
Cash and cash equivalents at the end of the period	299	131



